{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:53:39Z","timestamp":1794059619362,"version":"4.8.0"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We performed a pilot study of daratumumab (an mAb directed against CD38) in muscle-invasive bladder cancer (MIBC) and treatment-refractory metastatic renal cell carcinoma (mRCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Patients with MIBC underwent baseline transurethral resection of the bladder tumor followed by four weekly doses of daratumumab prior to cystectomy. Patients with mRCC underwent baseline and sequential biopsies after eight weekly doses. The primary endpoint was safety. The secondary endpoints were pathologic complete response rate for the MIBC cohort and objective response rate and progression-free survival for the mRCC cohort. Exploratory analyses included immune monitoring and overall survival. A Bayesian sequential monitoring design for toxicity was used for excessive toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In both the MIBC (n = 8) and mRCC (n = 8) cohorts, no toxicity events were encountered. In the MIBC cohort, one patient experienced pathologic complete response rate. In the mRCC cohort, no objective responses were reported, and the median progression-free survival was 1.5 months (95% confidence interval, 1.1\u20131.8 months). Immune monitoring found significant reductions in NK cells in circulation in both cohorts after treatment. In the tissue analysis, IHC found evidence of diminished CD38 presence in mRCC with treatment, whereas the baseline levels in MIBC were low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment with daratumumab was safe. No signal of efficacy was detected in mRCC, and conclusions on the activity in MIBC were limited. Evidence of daratumumab targeting CD38 was detected in circulating immune cells and within the tumor microenvironment of mRCC and MIBC.<\/jats:p>\n                    <jats:p>Significance: In this prospective clinical trial of daratumumab, treatment in patients with MIBC and mRCC was safe. Limited efficacy was observed. Treatment with daratumumab resulted in CD38-expressing immune cell subsets to be targeted both in circulation and within the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0237","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T09:30:38Z","timestamp":1724923838000},"page":"2444-2453","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-0621","authenticated-orcid":false,"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9599","authenticated-orcid":false,"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-3786","authenticated-orcid":false,"given":"Neema","family":"Navai","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-711X","authenticated-orcid":false,"given":"Colin P.N.","family":"Dinney","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0961","authenticated-orcid":false,"given":"Priya","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-3287","authenticated-orcid":false,"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-8985","authenticated-orcid":false,"given":"Rahul A.","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-0820","authenticated-orcid":false,"given":"Aradhana M.","family":"Venkatesan","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-8582","authenticated-orcid":false,"given":"Rebecca S.","family":"Tidwell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-5548","authenticated-orcid":false,"given":"Shalini S.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9233-8841","authenticated-orcid":false,"given":"Aidi","family":"Gu","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-0645","authenticated-orcid":false,"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"},{"name":"James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7282-6258","authenticated-orcid":false,"given":"Marc","family":"Macaluso","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"},{"name":"James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-0144","authenticated-orcid":false,"given":"Fei","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-3833","authenticated-orcid":false,"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"},{"name":"James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3911-6815","authenticated-orcid":false,"given":"Sonali","family":"Jindal","sequence":"additional","affiliation":[{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"},{"name":"James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-055X","authenticated-orcid":false,"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7"},{"name":"James P. Allison Institute, University of MD Anderson Cancer Center, Houston, Texas. 8"},{"name":"Department of Immunology, University of MD Anderson Cancer Center, Houston, Texas. 9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2025040317225573300_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib5","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cells9010052","article-title":"The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors","volume":"9","author":"Konen","year":"2019","journal-title":"Cells"},{"key":"2025040317225573300_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/cells9010026","article-title":"The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy","volume":"9","author":"Wo","year":"2019","journal-title":"Cells"},{"key":"2025040317225573300_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"2025040317225573300_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"2025040317225573300_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"2025040317225573300_bib12","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"2025040317225573300_bib13","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"key":"2025040317225573300_bib14","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1038\/s41467-021-26415-4","article-title":"Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma","volume":"12","author":"Campbell","year":"2021","journal-title":"Nat Commun"},{"key":"2025040317225573300_bib15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"2025040317225573300_bib16","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025040317225573300_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025040317225573300_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","article-title":"Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes","volume":"14","author":"Thall","year":"1995","journal-title":"Stat Med"},{"key":"2025040317225573300_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"key":"2025040317225573300_bib20","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025040317225573300_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"2025040317225573300_bib22","doi-asserted-by":"crossref","first-page":"1244494","DOI":"10.3389\/frhem.2023.1244494","article-title":"Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I\/II clinical trial","volume":"2","author":"Abdallah","year":"2023","journal-title":"Front Hematol"},{"key":"2025040317225573300_bib23","doi-asserted-by":"crossref","first-page":"e003697","DOI":"10.1136\/jitc-2021-003697","article-title":"Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I\/II open-label, multicenter study","volume":"10","author":"Zucali","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025040317225573300_bib24","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025040317225573300_bib25","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0237\/3491213\/crc-24-0237.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2444\/3498229\/crc-24-0237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2444\/3498229\/crc-24-0237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:56:58Z","timestamp":1743728218000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/9\/2444\/748470\/A-Pilot-Study-of-the-CD38-Antagonist-Daratumumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0237","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27044520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044487","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044481.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044517.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728479","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044499.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044520.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044496.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044490.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044493","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728491","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044511.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044487.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044493.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044484","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044496","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044505.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044484.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044478.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044514.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044508.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728488","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044502.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27044490","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728476","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728482","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728494","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7453158","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7453158.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}